Moderna’s COVID-19 Vaccine Shown to Be Effective in Adolescents

Moderna said its COVID-19 vaccine offered strong protection against infection in adolescents ages 12 to 17 years in a phase 2/3 study, paving the way for the company to seek a revised Emergency Use Authorization that covers this population.

In the 3,732-participant trial, the vaccine provided 93 percent efficacy two weeks after the first dose, climbing to 100 percent efficacy two weeks after the second dose, with no significant adverse events reported, the company said.

Participants in the trial will continue to be monitored for 12 months following their second shot.